GO
Loading...

Life Sciences

More

  • LOS ANGELES, Feb 19- As U.S. drugmakers face growing resistance to the high price of cutting-edge treatments, a handful of companies are working on a new payment model that rewards them for the long-term performance of their medicines. They include BioMarin Pharmaceutical Inc in San Rafael, California, and Sangamo BioSciences Inc in Richmond, California.

  • Regulus reports 4Q loss Wednesday, 18 Feb 2015 | 7:15 PM ET

    SAN DIEGO _ Regulus Therapeutics Inc. on Wednesday reported a loss of $22.2 million in its fourth quarter. The San Diego- based company said it had a loss of 47 cents per share. For the year, the company reported that its loss widened to $56.7 million, or $1.29 per share.

  • Pharmacyclics misses 4Q profit forecasts Wednesday, 18 Feb 2015 | 4:18 PM ET

    SUNNYVALE, Calif. _ Pharmacyclics Inc. on Wednesday reported fourth-quarter earnings of $63.5 million. The average estimate of analysts surveyed by Zacks Investment Research was for earnings of 90 cents per share. Pharmacyclics shares have risen 39 percent since the beginning of the year.

  • UMass reverses ban on Iranian science students Wednesday, 18 Feb 2015 | 2:20 PM ET
    UMass Amherst students on campus.

    UMass reversed a controversial policy change and continue to accept Iranian nationals into science and engineering programs, NBC News reports.

  • UPDATE 1-Novavax starts Ebola vaccine trial in humans Thursday, 12 Feb 2015 | 12:06 PM ET

    Feb 12- Novavax Inc has begun early-stage human trials of an Ebola vaccine that it hopes can win the race to become the most effective shot for the deadly virus. The company has the means to manufacture millions of doses of the vaccine every month and is seeking funding to develop it further, Chief Executive Stanley Erck told Reuters. Even as President Barack Obama...

  • Feb 10- Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp, after no additional qualified bids came forward by Tuesday's deadline, Valeant said. Valeant, of Laval, Quebec, will get Seattle- based Dendreon's Provenge cancer treatment and other assets for $400 million in cash. Dendreon and Valeant will seek court...

  • Feb 10- Valeant Pharmaceuticals International Inc appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process, three sources close to the sale told Reuters. Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge...

  • Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge cancer treatment.

  • LONDON, Feb 1- As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast. Determined not to lose scientific momentum that could make the world's first effective Ebola interventions a reality, researchers...

  • Jan 30- Shares of Spark Therapeutics Inc more than doubled in their debut, valuing the gene-therapy company at nearly $1.5 billion and underscoring investor's interest in the field that recently produced a million-dollar drug. The company's shares opened at $45.10 in their debut on Friday, nearly double their IPO price of $23, and soared to a high of $50 with...

  • Robert Califf, a top cardiologist and researcher, to oversee its drug, medical device and tobacco policy in what experts said is a coup for the FDA. "This is a great catch for the FDA," said Dr. Califf has run countless clinical studies, published more than 1,000 papers, served as an FDA adviser and has twice been interviewed as a potential FDA commissioner.

  • Jan 26- The U.S. Food and Drug Administration approved Rockwell Medical Inc's drug for treating iron loss in chronic kidney disease patients on dialysis, sending the company's shares up about 15 percent in premarket trading. Samimy said she expected Triferic to hit peak sales of $200 million- $250 million in the United States. Rockwell estimates the market for...

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been dispatched to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The World Health Organization said on Thursday the Ebola outbreak in West Africa, the worst in history, appears to be waning but cautioned against complacency.

  • LONDON, Jan 23- The first batch of GlaxoSmithKline's experimental Ebola vaccine has been shipped to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The vaccine, co-developed by the National Institutes of Health in the United States and Okairos, a biotechnology firm acquired by GSK in 2013, is currently being tested...

  • Jan 21- The U.S. Food and Drug Administration approved Novartis AG's injectable drug, Cosentyx, to treat adults with a moderate to severe skin disease called plaque psoriasis. Eli Lilly and Co will begin marketing its IL-17 inhibitor ixekizumab in the first half of 2015, while Amgen Inc and AstraZeneca Plc's brodalumab reported positive results from a...

  • The cost of halting a pandemic? $344 billion: Study Saturday, 17 Jan 2015 | 12:15 PM ET
    A custodial worker wears a mask and eye protection to guard against the Ebola virus as he prepares to clean Ruth Cherry Intermediate School in Dallas.

    How much would it cost world governments to insulate their economies from global pandemics. Would you believe nearly $344 billion?

  • LONDON, Jan 16- Johnson& Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros from Europe's Innovative Medicines Initiative to speed development. The new initiative will see J&J join with institutions including the London School of Hygiene& Tropical Medicine, the University of...

  • SHANGHAI, Jan 15- China has approved a new polio vaccine, the first of its kind to be produced in the country, a month after local authorities gave the green light for a home-grown Ebola vaccine amid Beijing's push to become a world leader in producing innovative drugs. "This new vaccine is a critically important weapon in the fight against polio as the world nears...

  • Jan 11- Canada's Tekmira Pharmaceuticals Corp agreed to buy Pennsylvania- based OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods. The implied market value of the merged company is about $750 million, based on Tekmira stock's closing price of $15.70 on the Nasdaq on Jan. 9, the companies said in a...

  • *Initial Phase I clinical study starts in Britain. *First tests in Britain, more planned in U.S. and Africa. LONDON, Jan 6- Johnson& Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.